• Daan D Wisselink, Linde L F Braakhuis, Gaetano Gallo, Wilhelmina M U van Grevenstein, Susan van Dieren, Kok Niels F M NFM Department of surgery, Antoni van Leeuwenhoek hospital, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands. Electronic a, Philip R de Reuver, Pieter J Tanis, and de Hingh Ignace H J T IHJT Department of surgery, Catharina hospital, Michelangelolaan 2, 5623 EJ Eindhoven, the Netherlands. Electronic address: Ignace.d.hingh@catharina.
• Department of Surgery, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105AZ Amsterdam, the Netherlands. Electronic address: d.d.wisselink@amc.uva.nl.
• Crit. Rev. Oncol. Hematol. 2019 Oct 1; 142: 119-129.

BackgroundThe role of hyperthermic intraperitoneal chemotherapy (HIPEC) with oxaliplatin in addition to cytoreductive surgery (CRS) has recently been questioned in peritoneal metastases of colorectal cancer. Whether this applies to all published CRS/HIPEC regimens is unclear.MethodsA systematic literature search identified 46 studies on CRS/HIPEC using either oxaliplatin of mitomycin C with at least one oncological outcome parameter RESULTS: Oxaliplatin and mitomycin C studies were comparable regarding extent of disease, but differed substantially regarding synchronous versus metachronous presentation, application of neo-adjuvant systemic chemotherapy, duration of HIPEC, and completeness of cytoreduction for at least one of the oncological endpoints. Severe postoperative complication rate seemed significantly higher after oxaliplatin-based CRS/HIPEC.ConclusionPublished cohorts on oxaliplatin-based CRS/HIPEC differed essentially from MMC-based procedures, especially considering the application of oxaliplatin-containing neo-adjuvant systemic therapy and shorter exposure time to intraperitoneal chemotherapy in oxaliplatin studies. No meaningful comparison could be made regarding DFS and OS.Copyright © 2019 Elsevier B.V. All rights reserved.

28 keywords...

hide…